Education
About Us
Working with TipRanks
Follow Us
IZRL - ETF AI Analysis
Top Page
ARK Israel Innovative Technology ETF (IZRL)
Rating:52Neutral
Price Target:―
Positive Factors
Broad Mix of Innovative Sectors
The fund spreads its investments across technology, health care, communication services, and other sectors, which helps reduce the impact if one industry struggles.
Strong Recent Performance in Top Holdings
Many of the largest positions have shown strong year-to-date gains, which has supported the ETF’s overall results.
Positive Short-Term Fund Performance
The ETF has delivered steady gains over the past month and quarter, suggesting recent momentum in its strategy.
Negative Factors
High Exposure to Technology
With about half of the portfolio in technology stocks, the fund is sensitive to downturns in the tech sector.
Concentrated in U.S. and Israel
Most of the holdings are in the U.S. and Israel, limiting diversification across other global markets.
Moderately High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can slightly reduce investors’ net returns over time.
IZRL vs. SPDR S&P 500 ETF (SPY)
AUM131.18M
RegionMiddle East & Africa
Expense Ratio0.49%
Beta0.83
IssuerARK
Inception DateDec 05, 2017
Dividend Yield2.74%
Asset ClassEquity
Index TrackedARK Israeli Innovation (USD)(TR)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume18,410
30 Day Avg. Volume20,975
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IZRL Summary
IZRL is the ARK Israel Innovative Technology ETF, which follows the ARK Israeli Innovation index and focuses on Israel’s fast-growing tech and innovation scene. It mainly holds technology and health care companies involved in areas like cybersecurity, artificial intelligence, and biotech. Examples of holdings include Nova and Bezeq. Someone might invest in IZRL to get diversified exposure to many innovative Israeli companies in a single fund, aiming for long-term growth from new technologies. A key risk is that it is heavily focused on tech and Israel, so its price can swing a lot and may drop sharply if those areas struggle.
How much will it cost me?The ARK Israel Innovative Technology ETF (IZRL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 you invest. This expense ratio is slightly higher than average because the fund is actively managed and focuses on a specific niche, requiring more research and management effort.
What would affect this ETF?The ARK Israel Innovative Technology ETF (IZRL) could benefit from global demand for advanced technologies like artificial intelligence and cybersecurity, areas where Israeli companies excel. However, geopolitical tensions in the Middle East or regulatory changes affecting tech companies could pose risks to its performance. Economic conditions, such as interest rate hikes, may also impact growth-focused sectors like technology.
IZRL Top 10 Holdings
IZRL is essentially a bet on Israel’s innovation engine, with tech and health care names setting the tone. Nova and Tower are helping drive the fund, riding steady to rising momentum tied to semiconductor demand, while Compugen adds a more volatile biotech flavor with mixed but improving sentiment. Industrial players like Ashot and Aryt have been quietly rising in the background, giving the portfolio some balance. Bezeq, a more traditional telecom, is only inching higher, acting more as an anchor than a sail in this all-Israel, tech-tilted lineup.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Bezeq | 1.95% | $2.56M | ₪22.79B | 59.45% | 75 Outperform | |
| Radware | 1.95% | $2.56M | $1.21B | 16.09% | 65 Neutral | |
| Camtek | 1.89% | $2.49M | $7.41B | 86.59% | 76 Outperform | |
| Partner | 1.85% | $2.43M | ₪7.49B | 57.56% | 72 Outperform | |
| Ituran Location And Control | 1.82% | $2.40M | $943.75M | 33.33% | 79 Outperform | |
| Tower | 1.77% | $2.33M | ₪44.52B | 170.29% | ― | |
| Urogen Pharma | 1.77% | $2.32M | $940.86M | 86.63% | 50 Neutral | |
| Teva Pharmaceutical | 1.77% | $2.32M | $39.33B | 109.11% | 63 Neutral | |
| Cellcom | 1.74% | $2.29M | ₪6.30B | 65.21% | 74 Outperform | |
| Ashot | 1.74% | $2.28M | ₪2.75B | 119.99% | ― |
IZRL Technical Analysis
Negative
―
Price Trends
30.07
Negative
29.14
Negative
27.39
Positive
Market Momentum
-0.52
Positive
36.85
Neutral
13.31
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IZRL, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 30.16, equal to the 50-day MA of 30.07, and equal to the 200-day MA of 27.39, indicating a neutral trend. The MACD of -0.52 indicates Positive momentum. The RSI at 36.85 is Neutral, neither overbought nor oversold. The STOCH value of 13.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IZRL.
IZRL Peer Comparison
Comparison Results
Performance Comparison
IZRL
ARK Israel Innovative Technology ETF
28.34
3.68
14.92%
TECB
iShares U.S. Tech Breakthrough Multisector ETF
―
―
―
FDTX
Fidelity Disruptive Technology ETF
―
―
―
LOUP
Innovator Loup Frontier Tech ETF
―
―
―
BCTK
Baron Technology ETF
―
―
―
ITEQ
BlueStar Israel Technology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents